Literature DB >> 34209213

Emerging Evidence for Pleiotropism of Eosinophils.

José M Rodrigo-Muñoz1,2, Marta Gil-Martínez1, Beatriz Sastre1,2, Victoria Del Pozo1,2,3.   

Abstract

Eosinophils are complex granulocytes with the capacity to react upon diverse stimuli due to their numerous and variable surface receptors, which allows them to respond in very different manners. Traditionally believed to be only part of parasitic and allergic/asthmatic immune responses, as scientific studies arise, the paradigm about these cells is continuously changing, adding layers of complexity to their roles in homeostasis and disease. Developing principally in the bone marrow by the action of IL-5 and granulocyte macrophage colony-stimulating factor GM-CSF, eosinophils migrate from the blood to very different organs, performing multiple functions in tissue homeostasis as in the gastrointestinal tract, thymus, uterus, mammary glands, liver, and skeletal muscle. In organs such as the lungs and gastrointestinal tract, eosinophils are able to act as immune regulatory cells and also to perform direct actions against parasites, and bacteria, where novel mechanisms of immune defense as extracellular DNA traps are key factors. Besides, eosinophils, are of importance in an effective response against viral pathogens by their nuclease enzymatic activity and have been lately described as involved in severe acute respiratory syndrome coronavirus SARS-CoV-2 immunity. The pleiotropic role of eosinophils is sustained because eosinophils can be also detrimental to human physiology, for example, in diseases like allergies, asthma, and eosinophilic esophagitis, where exosomes can be significant pathophysiologic units. These eosinophilic pathologies, require specific treatments by eosinophils control, such as new monoclonal antibodies like mepolizumab, reslizumab, and benralizumab. In this review, we describe the roles of eosinophils as effectors and regulatory cells and their involvement in pathological disorders and treatment.

Entities:  

Keywords:  biologic treatment; eosinophil; eosinophil extracellular traps; sub-phenotypes

Year:  2021        PMID: 34209213     DOI: 10.3390/ijms22137075

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  4 in total

Review 1.  Solving the Conundrum of Eosinophils in Alloimmunity.

Authors:  Cherie Alissa Lynch; Yizhan Guo; Zhongcheng Mei; Daniel Kreisel; Andrew E Gelman; Elizabeth A Jacobsen; Alexander Sasha Krupnick
Journal:  Transplantation       Date:  2021-12-27       Impact factor: 5.385

Review 2.  Peptide Targeting of PDZ-Dependent Interactions as Pharmacological Intervention in Immune-Related Diseases.

Authors:  Luis H Gutiérrez-González; Selma Rivas-Fuentes; Silvia Guzmán-Beltrán; Angélica Flores-Flores; Jorge Rosas-García; Teresa Santos-Mendoza
Journal:  Molecules       Date:  2021-10-21       Impact factor: 4.411

Review 3.  Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome.

Authors:  Dimitri Poddighe; Elena Kovzel
Journal:  J Inflamm Res       Date:  2021-12-14

4.  Improving Care in Eosinophil-Associated Diseases: A Charter.

Authors:  David J Jackson; Praveen Akuthota; Rebeca Andradas; Albert J Bredenoord; Amanda Cordell; Sarah Gray; Joyce Kullman; Sameer K Mathur; Ian Pavord; Florence Roufosse; Christian Rubio; Irena Clisson Rusek; Dagmar Simon; Mary Jo Strobel; Tonya Winders
Journal:  Adv Ther       Date:  2022-04-30       Impact factor: 4.070

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.